Search Results

You are looking at 141 - 150 of 1,601 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group*

summarize sample characteristics, analyze feasibility/acceptability, and summarize secondary outcomes. We compared self-efficacy scores preintervention and postintervention using multilevel models (MIXED function). Results Of 36 eligible and contactable

Full access

Understanding Comorbidity Profiles and Their Effect on Treatment and Survival in Patients With Colorectal Cancer

Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry, and Ernest Shen

adjusted for multiple pairwise comparisons between comorbidity classes by using the Bonferroni correction. Table 1. Patient Characteristics, Cancer Treatment, and Comorbidities Results We identified 7,803 patients with CRC ( Table 1

Full access

Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery

Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen, and Li Zhu

than stage IV, unknown demographic characteristics and follow-up, or unknown involvement of bone, brain, liver, or lung, and those diagnosed at autopsy or via death certificate were excluded. Eligible patients were divided randomly into the training or

Full access

Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series

Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao

of expression. After 3 cycles of pembrolizumab, restaging PET/CT demonstrated greater diminishment of the antral tumor and stable intrathoracic nodes. Table 1. Summary of Patient Characteristics, Treatments, and Responses Figure 1

Full access

Regional Variations in Clinical Trial Outcomes in Oncology

Brooke E. Wilson, Sallie-Anne Pearson, Michael B. Barton, and Eitan Amir

breast (n=23; 16%). The mean number of participating patients, sites, and countries were similar between studies that presented regional analyses and those that did not ( Table 1 ). Table 1. Baseline Trial Characteristics (N=147) Among all 147

Full access

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad

not available for analysis. Univariate analysis was applied to compare characteristics of participants who did and did not undergo surgical resection using Student t tests for continuous variables and Fisher exact for categorical variables

Full access

The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids

Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins

reported. A Bonferroni-adjusted type I error 2.5% (5%/2) was used for statistical significance. R version 3.4 (R Foundation for Statistical Computing) was used for all statistical analyses. Results Patient Characteristics, irAEs, and Use of SS and

Full access

Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta

resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease

Full access

Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework

Seanthel Delos Santos, Noah Witzke, Bishal Gyawali, Vanessa Sarah Arciero, Amanda Putri Rahmadian, Louis Everest, Matthew C. Cheung, and Kelvin K. Chan

assessed at the time of primary publication and at 3 years post-FDA approval using all publicly available data in eligible subsequent publications. Results Characteristics of Included Studies Of 113 indications that met the eligibility criteria, there were

Full access

Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

clinical variables. R version 3.6.1 (R Foundation for Statistical Computing) was used for statistical analyses. Results Patient Characteristics From 2001 through 2019, 68 clinical trials conducted at Gustave Roussy and Memorial Sloan Kettering